WO2006035414A3 - Carbidopa and levodopa dispersible tablets - Google Patents

Carbidopa and levodopa dispersible tablets Download PDF

Info

Publication number
WO2006035414A3
WO2006035414A3 PCT/IB2005/053219 IB2005053219W WO2006035414A3 WO 2006035414 A3 WO2006035414 A3 WO 2006035414A3 IB 2005053219 W IB2005053219 W IB 2005053219W WO 2006035414 A3 WO2006035414 A3 WO 2006035414A3
Authority
WO
WIPO (PCT)
Prior art keywords
levodopa
carbidopa
dispersible tablets
dispersible tablet
decarboxylase inhibitor
Prior art date
Application number
PCT/IB2005/053219
Other languages
French (fr)
Other versions
WO2006035414A2 (en
Inventor
Rajeev Shanker Mathur
Sameer Manan
Kamal Mehta
Original Assignee
Ranbaxy Lab Ltd
Rajeev Shanker Mathur
Sameer Manan
Kamal Mehta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Rajeev Shanker Mathur, Sameer Manan, Kamal Mehta filed Critical Ranbaxy Lab Ltd
Publication of WO2006035414A2 publication Critical patent/WO2006035414A2/en
Publication of WO2006035414A3 publication Critical patent/WO2006035414A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a dispersible tablet of levodopa and a decarboxylase inhibitor. The dispersible tablet includes levodopa, the decarboxylase inhibitor, and less than about 30% w/w of filler.
PCT/IB2005/053219 2004-09-30 2005-09-29 Carbidopa and levodopa dispersible tablets WO2006035414A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1894DE2004 2004-09-30
IN1894/DEL/2004 2004-09-30

Publications (2)

Publication Number Publication Date
WO2006035414A2 WO2006035414A2 (en) 2006-04-06
WO2006035414A3 true WO2006035414A3 (en) 2006-05-11

Family

ID=35589376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/053219 WO2006035414A2 (en) 2004-09-30 2005-09-29 Carbidopa and levodopa dispersible tablets

Country Status (1)

Country Link
WO (1) WO2006035414A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
CN114159417B (en) * 2021-04-20 2023-03-14 杭州泓友医药科技有限公司 Compound medicine for treating Parkinson's disease and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376545B1 (en) * 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
WO2003101432A1 (en) * 2002-05-29 2003-12-11 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376545B1 (en) * 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
WO2003101432A1 (en) * 2002-05-29 2003-12-11 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BETTINI R ET AL: "Influence of layer position on in vitro and in vivo release of levodopa methyl ester and carbidopa from three-layer matrix tablets", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 53, no. 2, March 2002 (2002-03-01), pages 227 - 232, XP004342818, ISSN: 0939-6411 *

Also Published As

Publication number Publication date
WO2006035414A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
WO2006091529A3 (en) A solid pharmaceutical dosage formulation
WO2005041924A3 (en) Administration of levodopa and carbidopa
WO2009071219A3 (en) Oral dispersable tablet
AU2003255845A1 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004060276A3 (en) Improved sunscreen compositions
AU2003290749A1 (en) Combined rankine and vapor compression cycles
AU2003293423A1 (en) Carbidopa prodrugs and uses thereof
WO2006081273A8 (en) 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
ZA200501431B (en) 5-Aryltetrazole compounds, compositions thereof, and uses therefor.
AU2003297676A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
AU2003280586A1 (en) Steam valve
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2004091645A3 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
AUPR981702A0 (en) Steam reformer
WO2003102012A3 (en) New etonogestrel esters
IL164856A0 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
GB2387192B (en) Self relieving seal
AU2003233426A1 (en) Corrosion inhibitor
WO2007141743A3 (en) A tablet dosage form comprising cetirizine and pseudoephedrine
WO2007028978A3 (en) Ramipril formulation
WO2006035414A3 (en) Carbidopa and levodopa dispersible tablets
WO2007077329A3 (en) New association of a sinus current if inhibitor and a calcic inhibitor, and pharmaceutical compositions containing the same
EP1880727A3 (en) Topical vaginal pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05787635

Country of ref document: EP

Kind code of ref document: A2